A Study of XmAb23104 in People With Sarcoma
Phase II Study of XmAb23104 (Targeting PD-1 and ICOS), in Patients With Advanced Sarcoma
Sponsor: Memorial Sloan Kettering Cancer Center
Terminated
Vendor decided study to be closed early
Other terminated trials from Memorial Sloan Kettering Cancer Center
- Acute Lymphoid Leukemia (ALL) · Phase PHASE2 · Mar 2024
- Gynecologic Surgery · Phase NA · Dec 2023
- Prostate Cancer · Phase PHASE2 · Jul 2023
- Diffuse Large B-Cell Lymphoma and Follicular Lymphoma · Phase PHASE1/PHASE2 · May 2023
- Small Cell Lung Cancer · Phase PHASE1/PHASE2 · May 2023
See all terminations from Memorial Sloan Kettering Cancer Center
A PHASE2 clinical study on Sarcoma, this trial is terminated or withdrawn. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 6 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jun 2023 — Nov 2023 [monthly]
Recruiting PHASE2
First recorded
Apr 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
- Xencor, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .